Team
An experienced, world-leading team.
Delmune Therapeutics brings together pharmacology and drug development experts, polymer chemists, nucleic acid delivery scientists, and a clinician-researcher specializing in immunology. Together, we combine over 75 years of translational research experience, anchored by 29 years of professorship pioneering non-viral gene delivery platforms, 16 years of frontline clinical care treating inflammatory diseases, and direct leadership in international medical societies that establish global disease classification standards.
- 75+
- Years of combined experience
- 29
- Years of professorship in non-viral gene delivery
- 16
- Years of clinical practice in these diseases
Hasan Uludag, PhD
President and Chief Executive Officer
Professor of Chemical and Materials Engineering at the University of Alberta. He has led research in non-viral gene delivery since 1993 and has held a professorship since 1997.
- University of Alberta Distinguished Professor
- Successful Entrepreneur
- Canadian Biomaterials Society Lifetime Achievement Award
- >250 publications
Full biography
Dr Uludag received the Canadian Biomaterials Society Lifetime Achievement Award in 2023. He has published more than 200 peer-reviewed papers on biomaterials and the delivery of nucleic acids.
He founded an earlier spin-off company that commercialised transfection reagents now sold internationally, which gives Delmune a founder who has already taken laboratory chemistry to a product.
Erkan Demirkaya, MD
Chief Medical Officer
Paediatric rheumatologist and Professor of Paediatrics at Western University. He is President of the International Society of Systemic Auto-Inflammatory Diseases, and treats patients with these exact conditions.
- Western University
- President, ISSAID
- Clinical practice since 2010
Full biography
Dr Demirkaya has practised as a clinician since 2010 and works with patients living with the autoinflammatory syndromes that Delmune’s lead program is designed for.
As President of the international society for these diseases, he works with the group that defines how they are classified. Target selection at Delmune was made by someone who sees the unmet need in a clinic rather than in a market report.
Mohammad Nasrullah, PhD
Chief Scientific Officer
Pharmaceutical scientist and pharmacology expert, and lead author of the technology study on which every efficacy claim on this company rests.
- Pharmacology Expert
- Rachel Mandel Scholar
- CSPS award recipient
Full biography
Dr Nasrullah is a Rachel Mandel Scholar in Lymphoma and other Blood Cancers and a recipient of a Canadian Society for Pharmaceutical Sciences award.
His published work spans lipopolymer delivery into leukaemia cells and immune cells, carrier biocompatibility, and silencing of the inflammasome in primary human cells.
Amarnath Rajendran, PhD
Chief Technology Officer
Synthetic chemist specialising in lipopolymer architecture, functionalised non-viral vectors and targeted delivery into chemo-resistant and refractory cells. He has worked in synthesis since 2010.
- Lipopolymer synthesis
- Non-viral vectors
- Synthesis since 2010
Full biography
Dr Rajendran designs and builds the carrier itself: the polymer backbone, the lipid substitutions that tune how it binds and releases its cargo, and the functional groups that steer it towards particular cells.
He is a co-author on the technology study and on the particle characterisation work published in Advanced Healthcare Materials.
Scientific advisors
Interested in working with us?



